Dynavax Technologies Corporation
$ 15.38
0.00%
26 Dec - close price
- Market Cap 1,805,996,000 USD
- Current Price $ 15.38
- High / Low $ 15.41 / 15.37
- Stock P/E N/A
- Book Value 4.55
- EPS -0.37
- Next Earning Report 2026-02-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE -0.07 %
- 52 Week High 15.49
- 52 Week Low 9.20
About
Dynavax Technologies Corporation (DVAX), based in Emeryville, California, is a biopharmaceutical leader specializing in the development and commercialization of groundbreaking vaccines designed to tackle significant public health challenges. The company has established itself through its innovative immunotherapy platform, notably with its flagship product, HEPLISAV-B, an advanced hepatitis B vaccine that has received approval in the U.S. and numerous international markets. With a robust pipeline of future products and strategic partnerships, Dynavax is positioned to make substantial contributions to global health by enhancing vaccine efficacy and addressing unmet medical needs. Its dedication to innovation and technology advancement establishes it as a pivotal entity within the dynamic vaccine industry.
Analyst Target Price
$20.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-07 | 2025-05-06 | 2025-02-20 | 2024-11-07 | 2024-08-06 | 2024-05-08 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-02 | 2023-02-23 |
| Reported EPS | 0.21 | 0.14 | -0.0091 | 0.05 | 0.12 | 0.08 | -0.07 | 0.0016 | 0.1 | 0.03 | -0.19 | 0.45 |
| Estimated EPS | 0.13 | 0.1 | 0.0123 | 0.04 | 0.11 | 0.06 | -0.02 | -0.01 | -0.01 | -0.09 | -0.13 | 0.43 |
| Surprise | 0.08 | 0.04 | -0.0214 | 0.01 | 0.01 | 0.02 | -0.05 | 0.0116 | 0.11 | 0.12 | -0.06 | 0.02 |
| Surprise Percentage | 61.5385% | 40% | -173.9837% | 25% | 9.0909% | 33.3333% | -250% | 116% | 1100% | 133.3333% | -46.1538% | 4.6512% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.08 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DVAX
2025-12-29 14:24:00
Sanofi has agreed to acquire Dynavax Technologies for approximately $2.2 billion, a deal expected to close in Q1 2026. This acquisition will add Dynavax's adult hepatitis B vaccine, HEPLISAV-B®, and a shingles vaccine candidate, Z-1018, to Sanofi's portfolio. The transaction enhances Sanofi's vaccine offerings with a currently marketed product and a promising pipeline candidate.
2025-12-29 12:09:24
Dynavax Technologies has entered into an Agreement and Plan of Merger with Sanofi, under which Sanofi will acquire Dynavax. Sanofi plans to launch a cash tender offer of $15.50 per share for all Dynavax shares, followed by a merger that will make Dynavax a wholly-owned subsidiary. The transaction aims to provide immediate cash value to shareholders and integrate Dynavax into Sanofi's global platform.
2025-12-28 10:59:00
Sanofi (NASDAQ: SNY) announced a definitive agreement to acquire Dynavax Technologies Corporation (NASDAQ: DVAX) for $15.50 per share in cash, valuing the deal at approximately $2.2 billion in equity. This acquisition aims to expand Sanofi's adult immunization presence, specifically leveraging Dynavax's marketed hepatitis B vaccine, HEPLISAV-B, and a shingles vaccine candidate. The deal, unanimously approved by Dynavax's board, is expected to close in Q1 2026 and will not impact Sanofi's 2025 financial guidance.
2025-12-27 09:09:07
Exchange Traded Concepts LLC significantly increased its stake in Dynavax Technologies Corporation by 50.4% in Q3, bringing its holdings to 200,976 shares valued at approximately $1.996 million. The biopharmaceutical company recently beat earnings estimates with $0.21 EPS on $94.88 million revenue, though it maintains a negative net margin and P/E ratio. Institutional ownership remains high at 96.96%, with analysts giving the stock a "Hold" consensus rating and a $24.33 price target.
2025-12-26 11:01:00
Dynavax Technologies Corporation (NASDAQ: DVAX) has been acquired by Sanofi (NASDAQ: SNY) for $2.2 billion, marking a significant turnaround for the biotech company. Once plagued by clinical setbacks, Dynavax pivoted its focus to become a leader in adult vaccines, primarily driven by its HEPLISAV-B Hepatitis B vaccine and CpG 1018 adjuvant. This acquisition validates Dynavax's strategic shift and successful commercialization efforts, providing Sanofi with a strong foothold in the growing adult immunization market.
2025-12-25 16:09:06
Dynavax Technologies Corp. (NASDAQ:DVAX) rallied 38.19% after announcing an agreement to be acquired by Sanofi for $2.2 billion. Sanofi will purchase all outstanding shares at $15.50 apiece to enhance its adult immunization portfolio, specifically with Dynavax's Heplisav-B hepatitis B vaccine and its shingles vaccine candidate. Dynavax CEO Ryan Spencer stated that joining Sanofi will provide the global scale and expertise to maximize its vaccine portfolio's impact.
